摘要
目的探讨乙型肝炎后肝硬化患者血清甲胎蛋白L3(AFP-L3)、高尔基体蛋白-73(GP-73)、癌胚抗原(CEA)与乙型肝炎病毒(HBV-DNA)载量之间的关系及在肝硬化分级中的价值。方法选取2015年8月至2016年8月该院收治的72例乙型肝炎患者为研究对象,分为肝硬化(LC)组40例、原发性肝癌(PHC)组32例,同期选取34例乙型肝炎表面抗体为阳性的健康人作为对照组,采用荧光定量聚合酶链式反应(FQ-PCR)检测HBV感染者血清HBV-DNA,利用双抗体夹心酶联免疫吸附试验(ELISA)检测所有受试者血清中AFPL3、GP-73、CEA水平。结果 LC组血清AFP-L3、GP-73、CEA水平均明显高于对照组,差异有统计学意义(P<0.05),PHC组血清AFP-L3、GP-73、CEA水平均明显高于LC组,差异有统计学意义(P<0.05);DNA阴性组血清AFP-L3、GP-73、CEA水平明显高于对照组,差异有统计学意义(P<0.05),且随着HBV-DNA载量增加呈明显升高趋势,差异有统计学意义(P<0.05);血清AFP-L3、GP-73、CEA水平随着肝功能Child-Pugh分级增加呈明显上升趋势,且两两比较差异有统计学意义(P<0.05);血清AFP-L3、GP-73、CEA水平与HBVDNA载量均呈正相关(r=0.582、0.521、0.630,P<0.05)。结论乙型肝炎后肝硬化患者血清AFP-L3、GP-73、CEA与HBV-DNA载量呈正相关,能够在一定程度上反映LC患者肝功能恶化程度,可作为LC诊断和判断病情进展程度的参考指标。
Objective To investigate the relationship between GP73,CEA,AFP-L3 and HBV-DNA,and their diagnostic value in the classification in patients with liver cirrhosis.Methods A total of 72 cases of hepatitis B were selected from August 2015 to August 2016 year in our hospital as the research objects,which 40 cases of LC,32 cases of PHC,and 34 cases of liver function examination surface antibody positive healthy were selected as the controls.DNA HBV was detected by FQ-PCR method,and AFP-L3,GP73 and CEA levels in all subjects were detected by ELISA.Results LC group of serum AFP-L3,GP73,CEA were significantly higher than the control group,the differences were statistically significant(P<0.05),PHC group of serum AFP-L3,GP73,CEA levels were significantly higher than those in group LC(P<0.05);The levels of serum AFP-L3,GP73 and CEA in the negative group were significantly higher than those in the control group(P<0.05),and increased with the increase of DNA HBV load(P<0.05);The levels of serum AFP-L3,GP73 and CEA increased with the increase of Child-Pugh(P<0.05);The serum levels of AFP-L3,GP73,CEA and DNA HBV were positively correlated(rs= 0.582,0.521,0.630,P<0.05).Conclusion The serum levels of AFP-L3,GP73,CEA are closely related to the persistent infection of DNA HBV,which may be used as serum markers for the diagnosis of LC and the monitoring of disease progression.
出处
《检验医学与临床》
CAS
2018年第3期320-322,共3页
Laboratory Medicine and Clinic
